nice find and nice article: Advanced Cell Technology applied to U.S. regulators last month to start human trials on its embryonic stem-cell treatment for Stargardt’s Macular Dystrophy, which causes untreatable blindness. The treatment resulted in 100 percent restoration of vision in rat studies with no serious side effects, Lanza said.
The stem-cell colony used in the studies, which wasn’t previously approved for federal research funding, is five to ten times as efficient at replacing lost photoreceptor cells as other lines, Lanza said.
The company plans to pursue the treatment for other forms of macular degeneration, which affects as many as 10 million people in the U.S., according to a company statement.
News 
Market Data 
Discover 
AI
